Wrong. Deal was always to close 2nd quarter. I don't know where you claim to get your information. Today, news is it should close late 1st quarter, early second, so the timeline is getting closer, not being pushed out as you suggest. Regulatory clearance around the world is whats holding it up.
It's "too" bad, not to bad Matsky old chum. Your points will be better accepted if you can express then intelligently and coherently. Now, why is it some people think it's the CEO's job to guarantee full employment? The reality is that an employee needs to provide more value than he costs or they are at risk. Companies often get bought out because they are loaded with unnecessary overhead and hence they are rife for a takeover. You want it any other way then go work for the govt.
Well, most of those middle class jobs are where the overlaps exist. You cant really have two accountants doing one job, or two lawyers, two HR officers/managers/directors etc etc.
Got to admire your staying power. Nah, this pig is done. The deal is being done and its a good move for both companies. There is lots there for both. Two great platforms to merge.
Actavis announced that it will pay $219 per share. $129.22 per share will be paid in cash, and Allergan shareholders will receive 0.3683 Actavis shares for each share of Allergan.
The total of cash and additional shares of ACT valued at the closing price today of 307.51 worked out to $242.48 per share paid (in cash and stock) for each share of AGN by Actavis.
You can contact AGN investor relations at 714-246-4636 for the treatment of the $129Exta cash portion of the "merger." BTW: ACT has scheduled an extraordinary gen. meeting on March 10, 2015 in Ireland. As an AGN or ACT holder, you might want to contact investor relations on your basic question. My first read kind was kind of set forth in legalize or accountancy jargon stating favorable treatment under the jurisdictions unless declared to not be so. I plan to ask my bookkeeper.
Anyone out there know where Mr Pyott will beheading after the take over is complete????
BioLargo (BLGO) and Lockheed have proven and game changing technologies to help create abundant water for everyone.
BioLargo’s AOS Filter close to commercialization while Lockheed’s Graphene Filter is about 3 to 5 years away.
To read report, copy and paste and google: Desalination Industry Screams for Cost Cutting Innovation: Lockheed And BioLargo Hold Key Technologies. Seeking Alpha.
BioLargo is Strong Buy with $3.00 12-month Price Target.
Sentiment: Strong Buy